In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EV3 and FoxHollow Merger Establishes Peripheral Leader

Executive Summary

FoxHollow's striking success in peripheral vascular disease was not lost on EV3, which, like FoxHollow, abandoned earlier efforts in coronaries to focus exclusively on peripherals. Now the companies are merging to form what is surely the biggest vascular device company dedicated to the peripheral market. (Sidebar to, "EV3/Novation: Can Group Contracting Work in High Tech?")

You may also be interested in...



Listerine, Tylenol Push J&J Consumer Health To 2020 Finish Line Against Pandemic Weight

Listerine mouthwash drove J&J’s oral care sales up 11.4% in the fourth quarter. Tylenol for adults was the star of its OTC drug business but weakness of children’s Tylenol products and other OTCs led to flat sales.

NB Pure Rolls Out As Brand For Sharpening Consumer Attention On Natural Wellness Line

Nutritional Brands rolls out NB Pure as brand, including logo, packaging design and website, for all its supplements after 25 years. “When you looked at our label for one brand and looked at the label for another brand, there was no symmetry between the two,” says CEO Danna Pratt.

Sanofi Steps Up To Lend A Hand Producing Pfizer/BioNTech's COVID-19 Vaccine In Europe

Sanofi will fill and package 100 million doses of a rival vaccine for the European market in 2021 in a sign of how the industry is working to meet an unprecedented demand for COVID-19 vaccines.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel